AKT1 and acute lymphoblastic leukemia: At the molecular level, IL-7 stimulation and IL-7R mutational activation promote T-ALL cell cycle progression and viability by activating oncogenic pathways such as PI3K/Akt/mTOR and JAK/STAT [12–14].